↓ Skip to main content

The recommendations of Chinese Parkinson’s disease and movement disorder society consensus on therapeutic management of Parkinson’s disease

Overview of attention for article published in Translational Neurodegeneration, June 2016
Altmetric Badge


50 Dimensions

Readers on

104 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
The recommendations of Chinese Parkinson’s disease and movement disorder society consensus on therapeutic management of Parkinson’s disease
Published in
Translational Neurodegeneration, June 2016
DOI 10.1186/s40035-016-0059-z
Pubmed ID

Shengdi Chen, Piu Chan, Shenggang Sun, Haibo Chen, Baorong Zhang, Weidong Le, Chunfeng Liu, Guoguang Peng, Beisha Tang, Lijuan Wang, Yan Cheng, Ming Shao, Zhenguo Liu, Zhenfu Wang, Xiaochun Chen, Mingwei Wang, Xinhua Wan, Huifang Shang, Yiming Liu, Pingyi Xu, Jian Wang, Tao Feng, Xianwen Chen, Xingyue Hu, Anmu Xie, Qin Xiao


Parkinson's disease (PD) is a chronic, progressive and debilitating disease, which affects over 2.5 million people in China. PD is characterized clinically by resting tremor, muscular rigidity, bradykinesia and postural instability. As the disease progresses, additional complications can arise such as non-motor and neurobehavioral symptoms. Pharmacological treatment and surgical intervention for PD have been implemented in China. Until 10 years ago, there was lack of standardization for the management of PD in different regions and among different physicians, leading to different treatment levels in different regions and different physicians. Since then, the Chinese Parkinson's Disease and Movement Disorder Society have published three versions of guidelines for the management of PD in China, in 2006, 2009 and 2014, respectively. Correspondingly, the overall level of treatment for PD in China improved. To update the treatment guidelines based on current foreign and domestic practice guidelines and clinical evidence, and to improve the treatment options available to physicians in the management of PD. A variety of treatment recommendations in the treatment guidelines have been proposed, including physical activity and disease-modifying medication, which should be initiated at the early-stage of the disease. The principles of dosage titration should be followed to avoid acute adverse reactions to the drugs, to achieve a satisfactory clinical effect with a low dose and to reduce the incidence of long-term motor complications. Moreover, different treatment strategies should be considered at different stages of the disease. Importantly, treatment guidelines and personalized treatments should be valued equally. A set of treatment recommendations has been developed to assist physicians to improve and optimize clinical outcomes for patients with PD in China.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 104 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 104 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 17 16%
Researcher 12 12%
Student > Bachelor 10 10%
Other 7 7%
Student > Ph. D. Student 7 7%
Other 19 18%
Unknown 32 31%
Readers by discipline Count As %
Medicine and Dentistry 18 17%
Neuroscience 11 11%
Biochemistry, Genetics and Molecular Biology 7 7%
Nursing and Health Professions 7 7%
Pharmacology, Toxicology and Pharmaceutical Science 6 6%
Other 18 17%
Unknown 37 36%